Table 1.
This table shows curation of genes identified in (A) etoposide /doxorubicin resistance or (B) susceptibility, their mechanism of action, means of experimental validation of the genes, correlation to survival, cancers in which they were identified, and the associated reference.
| Gene | Mechanism of involvement | Expression confers | Experimental evidence | Correlative evidence | Cancer type | Which drug | Reference |
|---|---|---|---|---|---|---|---|
| ETOPOSIDE RESISTANCE | |||||||
| KEAP1 | SWI/SNF chromatin remodeler, Top2 expression regulator | Resistance | RNAi | No | Melanoma | Etoposide, Doxorubicin, Daunorubicin, Aclarubicin | (16) |
| MDR1 | Drug transporter/ single nucleotide polymorphism | Resistance | Genotyping, Association studies | Yes-Human | Small cell lung cancer | Etoposide, Cisplatin | (45) |
| C9OrF82 | DNA damage response | Resistance | CRISPR cas9a | No | Melanoma | Etoposide, Doxorubicin, Daunorubicin, Aclarubicin | (16) |
| SMARCAB1 | Chromatin remodeler | Resistance | CRISPR cas9a | No | Melanoma | Etoposide, Doxorubicin, Daunorubicin, Aclarubicin | (16) |
| SMARCAE1 | Chromatin remodeler | Resistance | CRISPR cas9a | No | Melanoma | Etoposide, Doxorubicin, Daunorubicin, Aclarubicin | (16) |
| ElF4a1 | Translation initiation | Resistance | CRISPR cas9a | No | Melanoma | Etoposide, Doxorubicin, Daunorubicin, Aclarubicin | (16) |
| ABCB1 | Multidrug transporter | Resistance | CRISPR cas9a | No | Melanoma | Etoposide, Doxorubicin, Daunorubicin, Aclarubicin | (16) |
| CHEK2 | Cell cycle regulator | Resistance | RNAi | Yes- Mouse model | Lymphoma | Doxorubicin | (42) |
| TP53 | Genome maintenance | Resistance | RNAi | Yes- Mouse model | Lymphoma | Doxorubicin | (42) |
| TOP2A | DNA unwinding | Resistance | RNAi | Yes- Mouse model | Lymphoma | Doxorubicin | (42) |
| TOP2B | DNA unwinding | Resistance | RNAi | Yes- Mouse model | Lymphoma | Doxorubicin | (42) |
| ETOPOSIDE SUSCEPTIBILITY | |||||||
| SEMA5A | Channel protein | Susceptibility | GWAS | Yes- Human | Lymphoblastoid cell line | Etoposide | (46) |
| SLC7A6 | Solute carrier | Susceptibility | GWAS | Yes-Human | Lymphoblastoid cell line | Etoposide | (46) |
| PRMT7 | N methyltransferase enzyme | Susceptibility | GWAS | Yes-Human | Lymphoblastoid cell line | Etoposide | (46) |
| UVRAG | DNA damage response | Susceptibility | GWAS | Yes-Human | Lymphoblastoid cell line | Etoposide | (46) |
| ARID1A | SWI/SNF remodeler, inhibition sensitizes to Etoposide | Resistance | RNAi, microarray | Yes-Human | H1975, H2030, HCC4006, A549, HCC2450, PC9, Calu1, H1650, H522, H2126, H157, H1299, HCC15, HCC827, H322, H2009, Sw1573, Calu6, H441, HCC95, H520, H460, Calu3, H2122, H23, H3255 | Etoposide | (47) |
| EZH2 | Polycomb repressor complex | Resistance | RNAi, microarray | Yes-Human | H1975, H2030, HCC4006, A549, HCC2450, PC9, Calu1, H1650, H522, H2126, H157, H1299, HCC15, HCC827, H322, H2009, Sw1573, Calu6, H441, HCC95, H520, H460, Calu3, H2122, H23, H3256 | Etoposide | (47) |